The CIEA NOG mouse® was developed by Mamoru Ito of the Central Institute for Experimental Animals (CIEA) in Japan. The Prkdcscid mutation was identified by Mel Bosma of the Fox Chase Cancer Center in a C.B-17 congenic mouse population. This mutation was backcrossed onto the NOD/ShiJic strain at CIEA for at least eight generations. The Il2rg targeted mutation was developed by Dr. Kazuo Sugamura of Tohoku University by targeting the gene in ES cells derived from a 129 strain. Targeted ES cells were injected into C57BL/6 blastocysts. Resultant chimeras were backcrossed onto the C57BL/6JJic background for at least eight generations. The CIEA NOG mouse® was developed by backcrossing the C57BL/6JJic-Il2rg line to the NOD/ShiJic-Prkdcscid line for a total of eight generations. The B2m gene was knocked out via CRISPR-mediated knock-in of a nonsense mutation into exon 1. This mutation was made directly in the NOG strain.
Verma, B.; Ruggeri, B.; Dubé, P.; Volden, P.; Wesa, A. Unique Immunodeficient Murine Host Strains Impact Expansion and Engraftment of T cells in PBMC Humanized Mice. New York Academy of Sciences’ Frontiers in Cancer Immunotherapy. May 14-15, 2019; New York, NY.
Welcome! Tell us a little about yourself